The use of the opiate antagonist, @entity1510 , in the treatment of intractable XXXX .

@entity1 @entity75 @entity1510 @entity9479 @entity158 @entity1063
Thirteen adult @entity1 with @entity9479 , resistant to prior analgesic and other therapy, were treated with intravenous infusions of the opiate antagonist, @entity1510 . A total of twenty treatments were administered with doses of @entity1510 varying from 4.0-8.0 mgs. Seven @entity1 exhibited beneficial effects with the duration of the resultant @entity158 relief ranging from four days to two and a half years. In these @entity1 , @entity158 and hyperpathia were completely obtunded in six out of seven and partially in one. Side effects of therapy were minimal and of short duration being mainly confined to the cardiovascular system. During therapy all @entity1 had continuous E.C.G. monitoring. In certain ischaemic conditions of the central nervous system, endogenous opioids possibly reduce cerebral blood flow via. inhibition of the locus coeruleus and subsequent release of @entity1063 : hence @entity1510 by inhibiting the opioids could increase cerebral perfusion pressure. This study has shown the benefit of treating @entity1 with cerebral @entity75 with an opioid antagonist. The rapidity of onset of @entity158 relief in these @entity1 would appear to indicate a mode of action by increasing cerebral perfusion.
